Alphabet's AI drug startup Isomorphic Labs raises $5B
Isomorphic Labs has raised $5 billion in a Series C funding round led by Sequoia Capital and Greenoaks, Bloomberg reports. The Alphabet-owned startup led by Nobel laureate Demis Hassabis aims to develop new drugs using artificial intelligence. In a post on LinkedIn, Hassabis said Isomorphic is on track to "radically cut the time and cost to find new medicines." It is competing against other startups, including Chai Discovery, in a race to become the first biotech to launch an AI-designed drug that receives regulatory approval.
- Isomorphic Labs
- Pharma
- AI
- Pharmacy
- Venture Capital
- 999999999
- Views: 1,000,000,031
- Bookmark
- 0
Isomorphic Labs, the artificial intelligence drug discovery company owned by Alphabet, has raised $5 billion in a Series C funding round co-led by Sequoia Capital and Greenoaks. The financing represents one of the largest private fundraising rounds in biotechnology history and gives the London-based company substantial resources to accelerate its efforts to design and develop new medicines using artificial intelligence. Founded by Nobel laureate Demis Hassabis, Isomorphic is positioning itself at the forefront of a growing effort to transform pharmaceutical research through advanced computational models.
The funding round also included participation from Andreessen Horowitz and several other new investors, alongside continued investment from Alphabet. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated. The announcement described the round as oversubscribed, highlighting strong investor interest in the potential of AI-driven drug development. Isomorphic did not disclose its valuation as part of the official announcement, although earlier reports had indicated that the company was exploring a valuation of approximately $50 billion.
The new financing arrives just six months after Isomorphic raised $2.1 billion in its Series B round in May 2026. Combined with its earlier $600 million fundraising in March 2025, the company has now secured approximately $7.7 billion in disclosed funding. The scale and speed of these investments reflect growing expectations that artificial intelligence could reshape how pharmaceutical companies identify promising drug candidates, understand diseases and develop treatments.
At the center of Isomorphic's strategy is its proprietary drug design engine, known as IsoDDE. The platform combines multiple artificial intelligence models designed to simulate and analyze complex biological systems across different therapeutic areas and drug types. Rather than relying exclusively on traditional laboratory experimentation, the technology aims to predict how potential drug molecules will behave, helping researchers identify promising candidates and refine their molecular characteristics before advancing them through experimental testing.
The company's approach builds on scientific advances associated with Google DeepMind's AlphaFold, the artificial intelligence system that transformed researchers' ability to predict protein structures. Hassabis, who received the 2024 Nobel Prize in Chemistry alongside John Jumper for work related to protein structure prediction, founded Isomorphic Labs in 2021 as a spinout from DeepMind. The company's broader ambition is to apply similar computational breakthroughs to the much larger challenge of understanding biological interactions and designing medicines.
Isomorphic plans to use the new capital to expand its foundational AI models, deepen its understanding of disease biology and advance its internal drug development programs toward clinical trials. The company has reported positive preclinical results from programs focused on oncology and immunology. These findings suggest that its technology is producing candidates worthy of further investigation, although preclinical progress does not establish that a treatment will be safe or effective in human patients.
The company is also developing partnerships with established pharmaceutical manufacturers, including Eli Lilly, Novartis and Johnson & Johnson. These relationships allow Isomorphic to apply its computational drug design capabilities to research programs involving major industry participants with extensive experience in clinical development, regulatory requirements and commercial medicine production. The partnerships could provide additional opportunities to validate its technology across different therapeutic areas while expanding its potential drug pipeline.
Despite the excitement surrounding AI-driven drug discovery, the industry has yet to demonstrate that a fully AI-designed medicine can successfully progress through clinical development and receive regulatory approval. Drug discovery remains an exceptionally difficult process, with many promising candidates failing because of safety issues, insufficient effectiveness or unexpected biological responses. Artificial intelligence may help researchers narrow the search for viable molecules and reduce certain experimental costs, but it cannot eliminate the complexity of human biology or the extensive testing required before a new medicine reaches patients.
That challenge is central to the competitive landscape in which Isomorphic operates. The company faces competition from emerging biotechnology startups such as Chai Discovery, as well as other well-funded AI drug discovery businesses seeking to develop new approaches to molecular design. Larger pharmaceutical companies are also investing in artificial intelligence and building partnerships with technology firms. The race is increasingly focused on demonstrating measurable scientific progress rather than simply developing increasingly sophisticated AI models.
The $5 billion investment gives Isomorphic an opportunity to expand its research capabilities, recruit specialized scientific talent and build the infrastructure needed to move potential medicines through clinical development. It also raises expectations for the company to demonstrate that its technology can produce meaningful improvements in drug development timelines, costs and success rates. Investors will be looking for evidence that the company's computational predictions can translate into viable therapeutic candidates and, eventually, approved treatments.
For Hassabis, the latest financing represents a major commitment to his vision of applying artificial intelligence to some of medicine's most difficult problems. His ambition is to radically reduce the time and cost required to discover new medicines by using AI to model biological processes with greater precision. Whether Isomorphic can achieve that goal will depend on its ability to move beyond promising simulations and preclinical results into successful human trials.
The company's fundraising marks a significant moment for the intersection of artificial intelligence and biotechnology. With $5 billion in fresh capital and backing from some of the world's most prominent technology and investment firms, Isomorphic has the resources to pursue an ambitious drug development strategy. The ultimate test, however, will not be the amount of funding it raises or the sophistication of its models, but whether its technology can deliver safe, effective medicines that improve patient outcomes.
Reader Support
Support WebNovare
Send a crypto tip if this article helped you.
Log in or register to like, bookmark, watch tags, and comment.
Comments
No comments yet.
Log in or register to join the conversation.